Salman Hussain is a panelist during the conference. He is discussing patient-focused drug development, bringing a precision medicine approach to alopecia areata, and the latest patient reported outcomes tools and biomarker studies. The roundtable discussion includes representatives from several pharmaceutical companies, a couple physicians/researchers, and patient advocacy group members.
For more inforamtion on this event, click here.
Potential MFN impact
Reference country selection HHS provided guidance on setting benchmark pricing by considering the lowest price among a set of reference countries, defined by...